Professional Documents
Culture Documents
Malaria
Malaria
Malaria
Case Management
• Introduction
• Epidemiology
• Etiology
• Life cycle
• Clinical Manifestations
• Diagnosis
• Treatment
Introduction
• The most important of the parasitic disease of humans-107 countries, 3 billion people,
1-3 million deaths/yrly
• Eliminated from few countries but resurged in many parts of the tropics
• Post WWII, in 1955 the WHO launched its campaign to eradicate the disease
• This goal soon proved overly optimistic, and the campaign were discontinued in 1967
5
Intro…
•HCWs are expected to make an accurate diagnosis of malaria based on microscopic exam
of patient blood and multi-species RDT rather than relying on clinical assessment alone.
•Nurses at health facilities must provide optimal nursing care for hospitalized patients.
•Ensuring prompt and effective Rx of cases with uncomplicated malaria within 24hrs
after Sx onset will prevent most cases from progressing to severe and fatal illness.
6
• P. falciparum and P. vivax are the two dominant parasite species causing malaria in
Ethiopia, with relative frequencies of about 60% and 40%, respectively
• Major: Sep – Dec following the main rainy season from Jun to Aug.
• Major epidemics occur every 5-8 years, focal outbreaks are common.
• High immunity
• Lack of immunity
• Epidemic uncommon
• Epidemic common
• Children & pregnant women more affected.
Pathogenesis
• Man – Intermediate host.
• After bite of infected mosquito sporozoites are introduced into blood circulation
• Human infection begins when a female anopheline mosquito inoculates sporozoites from its salivary
• The swollen infected liver cells eventually burst, discharging motile merozoites into the
bloodstream
• After entry into the bloodstream, merozoites rapidly invade RBCs and become trophozoites
and multiply 6to20 fold every 48 h(P. knowlesi, 24 h; P. malariae,72 h)
• In P. vivax and P. ovale infections, a proportion of the intrahepatic forms remain inert for a period
ranging from 3 weeks to ≥1 year before reproduction begins
• These dormant forms, or hypnozoites, are the cause of the relapses that characterize infection with these
two species
• When the parasites reach densities of ~50/μL of blood the symptomatic stage of the infection
begins
• By the end of the intra erythrocytic life cycle, the parasite has consumed two-thirds of the
RBC’s hemoglobin and has grown to occupy most of the cell
• Hypoglycemia
• Metabolic Acidosis
• Principally caused by reduced delivery of oxygen to tissues, from the combined effects of
• Hypovolemia
18
Genetic Resistance
• 3.Thalassemia.
• 4.Glucose-6-phosphate-dehydrogenase deficiency.
19
Clinical features
• Malaria is a very common cause of fever in
tropical countries
• Febrile paroxysm:
• It comprises of 3 successive stages; cold stage, hot
stage, sweating stage
• The periodicity of the attack varies with the species: of the infecting parasite.
4. In P. falciparum typical tertian is not usual, so it is called malignant tertian (cold stage is less pronounced
• when the mature schizont ruptures releasing merozoites, malarial pigment and other parasitic debris.
• Macrophages engulf these and release endogenous pyrogens leading to pyrexia
21
Non-specific symptoms
Headache
Abdominal Discomfort
Fatigue
Muscle Aches
Chills And Rigor
Arthralgia And Myalgia
Diarrhea
Nausea, vomiting, and orthostatic hypotension
Severe normochromic, Hematocrit of <15% or hemoglobin level of <50 g/L (<5 g/dL) with
normocytic anemia parasitemia <10,000/μL
Bleeding/DIC Significant bleeding and hemorrhage from the gums, nose, and gastrointestinal tract and/or
evidence of disseminated intravascular coagulation
Convulsions More than two generalized seizures in 24 h; signs of continued seizure activity,
sometimes subtle (e.g., tonic-clonic eye movements without limb or face movement)
others
Hemoglobinuria Macroscopic black, brown, or red urine
Extreme weakness Prostration; inability to sit unaided
Hyperparasitemia Parasitemia level of >5% in nonimmune patients
(>10% in any patient)
Jaundice Serum bilirubin level of >3 mg/dL
if combined with a parasite density of 100,000/μL or other evidence of vital-organ dysfunction
24
Convulsions + + +++
• Chronic anemia .
• Failure to thrive.
26
Diagnosis of Malaria
• RDT
• PCR
Diagnosis
Clinical Diagnosis : Is by taking reliable history of the illness and performing a complete
physical examination.
• A patient from nonmalaria endemic area has fever or history of fever in the last 48 hours and has a history of
travel to malaria-endemic areas within the last 30 days.
• *Making the diagnosis of malaria on clinical features alone is not recommended, as this often has low specificity and
increases the chances of the patient being misdiagnosed
• Malaria should still be considered, even if the individual has another obvious cause for the fever
28
Dx Contd..
Parasitological Diagnosis
•Microscopic diagnosis and RDTs are the methods employed for confirmation of malaria etiology.
•Light microscopy using thick blood films can be very sensitive, detecting as few as 5 parasites/pl of blood.
•Thin blood film stained with Giemsa can identify malaria parasite species and has a sensitivity of 20 parasites/pl.
•Parasite load is determined by quantifying the number of malaria parasites per microliter of blood on thick blood film.
•Multispecies RDTs capable of detecting both P. falciparum and P. vivax, are enhancing malaria diagnosis by species at the
periphery and reducing the need for empiric treatment and wastage of drugs.
•Patients who test negative by malaria RDT or microscopy DO NOT need antimalarial medications.
29
• Thick and thin blood smears should be prepared and examined by experienced personnel
immediately to confirm the diagnosis and identify the species of infecting parasite
30
• Thick smears
• Concentrate red cell layers approximately 40-fold and are used to screen a
relatively large amount of blood for the presence of parasites.
• Because red cells are lysed in the process of staining in the thick smear
technique, parasites are visualized outside red cells
RDT
• Rapid, simple, sensitive, and specific antibody-based diagnostic stick or
card tests
• Nucleic acid tests (eg, PCR) are typically used as a gold standard in efficacy studies
for antimalarial drugs, vaccines, and evaluation of other diagnostic agents
33
Treatment Approach
•Rx of malaria should be based upon a parasitologicaly confirmed Dx whenever situations
permits
•The first dose should be given under direct supervision of the health worker.
•If vomiting occurs within half an hour after the patient swallows the drug, the dose should be
repeated
34
Contd..
• Take detailed history (including travel history of the suspected case)
• Do thorough Physical examination and clinically assess for other causes of fever
• Other laboratory investigations to aid diagnosis and to rule out other medical conditions
resembling malaria
• WHO recommends that artemisinin-based combination therapies (ACTs) be used for the
treatment of uncomplicated P. falciparum malaria
Artemether-lumefantrine
Artesunate-mefloquine
Dihydroartemisinin-piperaquine
Artesunate-sulfadoxine-Pyrimethamine
Artesunate-amodiaquine
36
• Dihydroartemisinin
• Artesunate and
• Artemether...
• Quinine
• Schizonticidal for all, gametocytocidal for p.v and p.m but not p.f
37
• AL tablets are given according to body weight in six doses over three days
• Treat infants weighing < 5 kg with uncomplicated malaria with AL per body weight target dose
• The first dose should be given under direct supervision of the health worker.
• AL should preferably be taken with food or fluids.
• A fatty meal or milk improves absorption of the drug.
• If vomiting occurs within half an hour swallowing the drug, the dose should be repeated
and should be provided with a replacement dose to ensure completion of treatment
38
• The first line drug of choice is chloroquine plus 14 days primaquine radical cure.
• 10 mg base/kg po (Day 1), 10 mg base/kg po at 24 hrs (Day 2), and 5mg base/kg po at 48 hrs (Day 3)
• NB: do not treat confirmed mixed infection with both AL and chloroquine.
• If the result of the multi-species RDT is negative for all malaria species, malaria is
unlikely. Other causes of fever should be investigated.
40
41
42
• If AL is not available for P. falciparum or mixed malaria infections, use oral quinine.
• If both chloroquine and AL are not available for P. vivax infection, use oral quinine.
43
Supportive treatment
• If patients with axillary temperature record of ≥37.5o C , treat with antipyretics
• Paracetamol (acetaminophen) 15 mg/ kg every 4 hours is widely used; it is safe and well tolerated, given
orally or as a suppository
Referral
• It is important that all patients be assessed for the presence of danger signs
• If a patient presents with danger signs or found to have any of the danger signs, they require URGENT
medical attention and should be referred to a higher-level facility as soon as possible.
44
Clinical Danger Signs • Any patient presenting with any of the danger signs, should be referred to the next higher-
level health facility as soon as possible.
• Children < 6 yrs should be given pre-referral RX
Pre-referral treatment:
• The conscious patient:
• single dose of rectal artesunate (10mg/kg)
• Do not use rectal artesunate in older children and adults.
• Patients older than six years should be referred immediately to higher health facility for
further investigation and management ·
• If high fever is present, give paracetamol
• Encourage fluid intake during the transfer; continue breastfeeding in young infants; ·
• The unconscious patient:
• Ensure the airway is not blocked ·
• Show family members how to position the patient on side
• Give rectal artesunate as a pre-referral treatment
• give paracetamol suppositories for high fever
45
Treatment Failure
• Failure of antimalarial drug to resolve fever and/or parasitemia.
• For clinical purpose, consider treatment failure in a patient tested positive for malaria who was treated for malaria
Drug Resistance,
Poor Adherence Or Inadequate Drug Exposure (I.E. From Under-dosing, Vomiting Or Unusual Pharmacokinetic
Drug Interaction,
Misdiagnosis Or
Substandard Medicines.
• Monitoring treatment failure is very important because it can signal the appearance of anti-malarial drug resistance
46
• The majority of treatment failures occur after two weeks of initial treatment.
In patients who are suspected to have Rx failure after 28 days, the first-line anti-malarial drug should be used;
47
Cont’d
• Second-line treatments for recrudescence following first-line therapy,
Poor adherence
• Monitoring of the level of parasitemia linked to the clinical evolution of the patient.
• In non-immune individuals, high numbers of parasites (>4% parasite density or >200,000 parasites per ul of blood) is
generally associated with severe disease.
• If clinical features strongly suggest severe P. falciparum malaria, treatment maybe started, even though results are not
yet confirmed.
• Other essential laboratory tests (where available) to aid management of the severe malaria
patient and differential diagnosis
• IM artemether (alternate) OR ·
• Once the patient with severe malaria regains consciousness and tolerates oral therapy,
• A full course of oral AL therapy should be started to complete the treatment for P. falciparum cases
• A full course of oral chloroquine and a 14-day primaquine should be given for P. vivax cases.
52
• After initial resuscitation, assess and record the GCS or Blantyre score
• Correct hypoglycaemia
• Re-check blood glucose every 2-4 hours during the course of treatment, particularly in the
pregnant or comatose patient because hypoglycemia can recur even after an IV bolus of glucose.
• Malaria in pregnancy is associated with premature labor, low birth weight, anemia, and risk of development of severe malaria
• Pregnant women with symptomatic acute malaria are a high-risk group and must promptly receive effective anti-malaria
treatment.
• The 1st-line treatment for P. F infection in pregnant women in the 1st trimester of pregnancy is PO quinine
• AL is indicated in first trimester pregnancy only if this is the only treatment available for P.F
• If pregnant women have P. F or mixed infection in their second or third trimester, they will be treated with AL.
• Pregnant women with only P. vivax will be treated with chloroquine in all trimesters
• Treatment for severe malaria in pregnant women is Artesunate Injection or alternatively Artemether IM during the second and third trimester or
• Primaquine is contraindicated in all trimester of pregnancy and lactating mothers during the first 6 months
• Chloroquine is a safe drug that can be used in all children with only P. vivax infection
HIV
• Treatment of malaria is similar in HIV-infected and HIV-uninfected patients.
Thank You